Sign in Subscribe

Alex Chompff

Circulating Tumor DNA May Guide Adjuvant Chemotherapy After Liver Metastasis Surgery

Skip to content The CRC Digest ◇ RESEARCH Circulating Tumor DNA May Guide Adjuvant Chemotherapy After Liver Metastasis Surgery Circulating tumor DNA for molecular residual disease tracking could help identify patients with colorectal cancer and liver metastases who are most likely to benefit from adjuvant chemotherapy after surgery, according to overall

FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults

Skip to content The CRC Digest ▪ SCREENING FDA Approves SimpleScreen CRC Blood Test for Average-Risk Adults The FDA has approved SimpleScreen CRC, a new blood-based screening option for colorectal cancer in adults aged 45 years and older who are at average risk, based on data from the PREEMPT CRC trial.

CRC Research Update — August 15, 2026

Today's colorectal cancer research highlights

Multimodal deep learning model predicts MSI status from CT and pathology

Skip to content The CRC Digest Multimodal deep learning model predicts MSI status from CT and pathology Researchers developed a multimodal deep learning model integrating CT radiomics and histopathologic pathomics for predicting microsatellite instability in colorectal cancer, enrolling 509 patients from two medical centers. (Academic Radiology) This content is informational

Mexico sees marked increase in CRC among adults under 50

Skip to content The CRC Digest Mexico sees marked increase in CRC among adults under 50 A narrative review of epidemiological studies demonstrates a marked increase in CRC incidence and mortality in Mexico over the last two decades, with a disproportionate impact on adults under 50 years of age. (Cureus)

Significant discrepancies found in early-onset CRC among neglected populations

Skip to content The CRC Digest Significant discrepancies found in early-onset CRC among neglected populations A comprehensive review evaluating genetic and molecular research on hereditary and early-onset CRC in ethnic minority, indigenous, and understudied populations found significant discrepancies in early-onset CRC presentations compared with well-studied groups, despite largely consistent Lynch

Adjuvant chemotherapy benefits occur early, not in late recurrences

Skip to content The CRC Digest ◆ TRIAL DATA Adjuvant chemotherapy benefits occur early, not in late recurrences A systematic review of phase III randomized controlled trials for gastrointestinal malignancies including colorectal cancer found that recurrence-free survival improvements were driven by early divergences during active chemotherapy, while late recurrences were not

New gene circuit platform targets multiple KRAS mutations in preclinical models

Skip to content The CRC Digest ◇ RESEARCH New gene circuit platform targets multiple KRAS mutations in preclinical models Researchers developed a platform that enables in vivo self-assembly of small extracellular vesicles encapsulating KRAS-specific siRNAs for broad targeting of KRAS mutants, showing activity in orthotopic models of KRAS G12D-, G12V-, and

Trifluridine/tipiracil outcomes examined in patients 75 and older

Skip to content The CRC Digest ▸ TREATMENT Trifluridine/tipiracil outcomes examined in patients 75 and older A single-center retrospective study compared relative dose intensity, toxicity, and survival between trifluridine/tipiracil (FTD/TPI) monotherapy and FTD/TPI plus bevacizumab in older patients with metastatic colorectal cancer, examining the relationship between dose

Multitarget stool DNA test shows promise over standard FIT screening

Skip to content The CRC Digest ▪ SCREENING Multitarget stool DNA test shows promise over standard FIT screening A systematic review found that multitarget stool DNA (mt-sDNA) testing emerged as a promising alternative to faecal immunochemical test (FIT) for detecting colorectal neoplasms, particularly given FIT's low sensitivity for advanced